Health and Healthcare
Why This FDA Departure Is Huge for Sarepta
Published:
Last Updated:
Sarepta Therapeutics Inc. (NASDAQ: SRPT) closed out Wednesday with its shares up over 25% following positive developments surrounding eteplirsen, its treatment of Duchenne muscular dystrophy. Although this development is not truly definitive in what will happen with the appeal, it does yield some optimism for the patients and parents of the patients in extending the trial.
Dr. Ronald Farkas was the lead on a critical U.S. Food and Drug Administration (FDA) review of eteplirsen, but it was reported that he would be leaving this position. Previously, the Wall Street Journal had reported that Farkas was the most vocal critic of this drug, although he is not the only member of the 13-person committee that has concerns on the drug.
In particular Farkas took issue with the randomized controlled trials and open-label extension studies conducted by the sponsor. However, many of the critics against Farkas pointed to the safety and efficacy data from the trials, which should provide an avenue for continuation.
With the Farkas departure seemingly removing the largest obstacle to a regulatory approval, the bulls took over and pushed even higher. More bearish investors could argue that despite Farkas leaving, not much will change from the FDA. But the question is how do you price these opposing views into the stock?
If eteplirsen is not approved, then not much has changed; the stock had already bottomed from this news at its price level prior to Wednesday’s move. However, should the drug win approval and come back online, Sarepta stands to have some serious upside.
Excluding Wednesday’s move, Sarepta has underperformed the broad markets, with the stock down about 34% year to date. Over the past 52 weeks, the stock is down 30%.
Shares of Sarepta closed Wednesday up nearly 27% at $32.45, with a consensus analyst price target of $21.00 and a 52-week trading range of $8.00 to $41.97.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
